SCHEMBL4879896

SCHEMBL4879896

O=C(O)NC1CCC(NC(=O)c2cc(F)cnc2Nc2ccc(F)c(F)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.49
PDE4D Q08499 2/20 0.49
PDE4A P27815 1/20 0.49
AURKA O14965 1/20 0.44
AURKB Q96GD4 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 2/20 0.41
KCNQ3 O43525 1/20 0.41
KCNQ2 O43526 1/20 0.41
DGAT1 O75907 1/20 0.40
CRHR1 P34998 1/20 0.40
EGFR P00533 1/20 0.40
BTK Q06187 1/20 0.40
PIM1 P11309 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
PTK2 Q05397 2/20 0.39
AXL P30530 1/20 0.39
MCHR1 Q99705 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4879890 1.00 PDE4B (0.49) PDE4BPDE4DPDE4AAURKAAURKB
SCHEMBL4772447 0.88 NPC1 (0.44) PDE4BPDE4DPDE4AAURKAAURKB
SCHEMBL3022489 0.84 EGFR (0.44) PDE4BPDE4DPDE4AAURKAAURKB
SCHEMBL3022482 0.84 EGFR (0.44) PDE4BPDE4DPDE4AAURKAAURKB
SCHEMBL4872296 0.84 NPC1 (0.40) PDE4BPDE4DPDE4ANPC1RAB9A
SCHEMBL4879863 0.84 NPC1 (0.40) PDE4BPDE4DPDE4ANPC1RAB9A
SCHEMBL4770078 0.84 BRD4 (0.46) PDE4BPDE4DPDE4AAURKAAURKB
SCHEMBL4880802 0.82 MAPT (0.51) PDE4BPDE4DPDE4ANPC1RAB9A
SCHEMBL4880785 0.82 MAPT (0.51) PDE4BPDE4DPDE4ANPC1RAB9A
SCHEMBL4874446 0.81 CAMK1D (0.42) PDE4BPDE4DPDE4AEGFRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases ASTRAZENECA AB (SE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases PDE4A, PDE4B, PDE5A PDE4B 2/4885PDE4D 7/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.